Washington, D.C.-Based Whitman-Walker Clinic Announces Staff, Program Reductions

The Whitman-Walker Clinic — a not-for-profit health organization that is the largest HIV/AIDS service provider in the Washington, D.C., area — on Tuesday announced that it will be reducing some staff and programs, the Washington Post reports. The clinic announced that it plans to close its office in Northern Virginia, which provides services to 1,100 clients, and shut down an eight-bed residential addiction program in the district. The clinic also announced that it will lay off 45 employees.

Gordon Brown Praises NHS Staff On Reductions In C. Difficile And MRSA Infections, UK

NHS staff should be “proud of their achievements” the PM says following news of large reductions in C.difficile and MRSA infections.

Health Protection Agency figures released earlier today show that the rate of infection has been reduced by more than a third in the last 12 months.

MRSA infections are now down 57 per cent since 2004, exceeding the NHS target.

In a letter to health professionals, Mr Brown said that the “tremendous achievement” would protect the reputation of the NHS as one of the country’s greatest institutions.

Onglyza (saxagliptin) Demonstrated Significant Reductions In Key Measures Of Glucose Control In Treatment Naïve People With Type 2 Diabetes

Results from a 24-week Phase III study presented at the 68th American Diabetes Association Annual Scientific Sessions demonstrated that saxagliptin, a selective, reversible inhibitor of the dipeptidyl peptidase (DPP-4) enzyme in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), produced significant reductions in key measures of glucose control (glycosylated hemoglobin level [A1C], fasting plasma glucose [FPG] and postprandial glucose [PPG]) in treatment naïve people with type 2 diabetes compared to placebo (PBO). Over 24 weeks, saxagliptin had an adverse event profile that appeared similar to placebo. The companies have proposed the trade name ONGLYZA™ for saxagliptin if approved by the U.S. Food & Drug Administration.

Onglyza (saxagliptin) Demonstrated Significant Reductions In Key Measures Of Glucose Control In Treatment Naïve People With Type 2 Diabetes

Results from a 24-week Phase III study presented at the 68th American Diabetes Association Annual Scientific Sessions demonstrated that saxagliptin, a selective, reversible inhibitor of the dipeptidyl peptidase (DPP-4) enzyme in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), produced significant reductions in key measures of glucose control (glycosylated hemoglobin level [A1C], fasting plasma glucose [FPG] and postprandial glucose [PPG]) in treatment naïve people with type 2 diabetes compared to placebo (PBO). Over 24 weeks, saxagliptin had an adverse event profile that appeared similar to placebo. The companies have proposed the trade name ONGLYZA™ for saxagliptin if approved by the U.S. Food & Drug Administration.